BIOEMTECH

The enterprise was funded by the ‘Competitiveness’ Programme (NSRF 2021-2027) Action ‘Basic Digital Transformation for SMEs’ of the ‘Digital Transition for SMEs’ Package of Actions. The Action aims at covering the basic needs of SMEs with modern information and communication technologies that contribute to an outward-looking, innovative, and competitive production of products or services.

📢 Imaging of another exotic RLT radionuclide – Ag¹¹¹ 🤝 Our collaborator, Mattia Asti, will present at the 5th Italian Conference on Advanced Therapies and Innovative Radiopharmaceuticals on September 17th, in a talk titled “New radionuclides for diagnostic and therapeutic applications”, showcasing results from our joint study on Ag¹¹¹ imaging and quantification. 💊 RadioLigand Therapy (RLT) delivers radionuclide-labeled molecules directly to tumors, combining molecular specificity with the cytotoxic effects of ionizing radiation. Imaging is essential here, ensuring efficacy, safety, and accurate dosimetry, though challenges remain due to complex γ-ray spectra and high scatter. 🔬 Ag¹¹¹ is a medium-energy β-emitter (with a half-life of 7.45 days) with particulate emissions suitable for medium to large tumors. Its γ-emissions, notably at 342 keV, provide a theranostic advantage by enabling therapy monitoring through SPECT. However, multiple γ peaks make imaging particularly demanding. ✅ At BIOEMTECH, we addressed these challenges through phantom studies, demonstrating the feasibility of Ag¹¹¹ imaging across three energy windows. These findings pave the way for 𝘪𝘯 𝘷𝘪𝘷𝘰 validation, as we continue exploring Ag¹¹¹’s potential in preclinical settings. #RadioLigandTherapy, #Theranostics, #Ag111, #InVivoImaging, #PreclinicalResearch

Το Hellenic Digital Health Cluster (HDHC) Digital Health Cluster - HDHC σε συνεργασία με το Eθνικό Κέντρο Τεκμηρίωσης και Ηλεκτρονικού Περιεχομένου - National Documentation Centre (EKT), εκπρόσωπο του EIT Health στην Ελλάδα, πραγματοποιούν διαδικτυακό εργαστήριο του έργου SymbIASIS, την Πέμπτη 11 Σεπτεμβρίου 2025 (16:00 – 17:00) με τίτλο “Hellenic Digital Health Cluster: Inspiration by Τop Innovators". Συμμετέχουν και παρεμβαίνουν: - Marios Roides και Zoe D. Atsipoulianaki, EIT Health HUB, Eθνικό Κέντρο Τεκμηρίωσης και Ηλεκτρονικού Περιεχομένου - National Documentation Centre (EKT) - George D., Cluster Manager, Hellenic Digital Health Cluster (HDHC) - Panagiotis Papadimitroulas, Co-Founder | Head of Software, BIOEMTECH - Emmanouil Spanakis, COO, TRAQBEAT TECHNOLOGIES PC Tο εργαστήριο απευθύνεται στις νεοφυείς επιχειρήσεις που συμμετέχουν στο έργο SymbIASIS, στο Elevate Greece και στα μέλη του HDHC. #HDHC #Symbiasis #Webinar

Last week in London, BIOEMTECH had the honor to actively contribute to the 2nd SMARTdrugs Annual Meeting and related scientific events, highlighting our expertise in real-time 𝑖𝑛 𝑣𝑖𝑣𝑜 molecular imaging and radiotheranostics. 🎓 At King's College London – SΤ Thomas Hospital, our Science & Innovation Manager Maria Kitsara gave a talk to faculty members entitled: “Real-Time 𝑖𝑛 𝑣𝑖𝑣𝑜 Molecular Imaging of Radiopharmaceuticals: Innovation Aligned with the 3Rs”. After the presentation, a tour of the St Thomas’ Hospital lab followed, where our β-eye™ imaging system is installed. 🔬 At the SMARTdrugs Annual Meeting at the London Institute for Healthcare Engineering, Maria shared another perspective with the talk: “Feasibility Study on 𝑖𝑛 𝑣𝑖𝑣𝑜 Isolation of Daughter Isotopes from Therapeutic Alpha-Emitting Radiopharmaceuticals”. She highlighted the ongoing work and progress in imaging alpha-emitters, a particularly challenging endeavor that requires both technical innovation and perseverance. 🤝 We were also delighted to see our technology showcased by Rosie Lewis, who presented her work “Imaging the chickCAM model on the β-eye™”, demonstrating how 𝑖𝑛 𝑜𝑣𝑜 molecular imaging can provide valuable insights at very early research stages, underlining the value of collaborative research. This meeting was a reminder of the impact that imaging technologies can bring to the development of next-generation radiopharmaceuticals and of the strength of working together across academia and industry. 🙏 Special thanks to Tim Witney and his team for the excellent organization of the meeting, and to Angela Casini, SMARTdrugs project coordinator, for keeping the consortium on track and inspired. We are proud to be part of the SMARTdrugs project and excited for what lies ahead! 🚀 #EUproject #Radiopharmaceuticals #MolecularImaging #Oncology #InOvo

#Bioluminescence and #Fluorescence Imaging with φ-eye™ 🔬 In this study conducted in collaboration with the LBMI at FORTH-IESL team and led by Giannis Zacharakis, a mouse 🐭 bearing a subcutaneous U87MG_Luc2 tumor was monitored over time. The combination of bioluminescence (BLI) and fluorescence (FLI) provided complementary insights into tumor progression and tracer distribution. 🌟 Bioluminescence Imaging (#BLI): By administering D-luciferin (IVISbrite RediJect), the luciferase-expressing tumor cells produced light that could be detected 𝑖𝑛 𝑣𝑖𝑣𝑜. Over the course of the study, the signal remained relatively stable during the early days and showed a sharp increase after day 49, reflecting the active proliferation of tumor cells. 🧪 Fluorescence Imaging (#FLI): A near-infrared (NIR) fluorescent tracer was also used to visualize biodistribution. The images revealed tracer accumulation in the tumor region, but also in clearance organs such as the liver and intestines, which is typical for such probes. 📈 Kinetic and Growth Analysis: The luciferin kinetic curve shows the expected pattern: a peak intensity around 18–20 minutes post injection, followed by a gradual decline. Tumor growth analysis confirmed a delayed expansion phase, followed by rapid increase in tumor area after approximately 7 weeks. 📢 Conclusion: The results demonstrate how φ-eye™ enables non-invasive, longitudinal monitoring of tumor growth and tracer biodistribution in small animals. By combining BLI and FLI, researchers can gain valuable insights into both cellular activity and drug behavior over time. 👉 Click the link to explore the system capabilities: https://lnkd.in/dpMj_xKU #TumorGrowth #TracerBiodistribution #Oncology

🎤 #FFplus Business Interviews are highlighting how innovative #SMEs are harnessing #HPC and #AI to transform their businesses through the #FF4EuroHPC and #FFplus initiatives! In this interview, we speak with Panagiotis Papadimitroulas, Associate Professor of Biomedical Informatics at the University of Thessaly and co-founder and software advisor at BIOEMTECH. Bioemtech is a Greek specialised organisation that provides services to assist pharmaceutical and biotechnology companies. 💡 Panagiotis explained how Bioemtech is accelerating preclinical research, towards clinical translation for promising drugs, through our high-quality services and products. He also shares insights from their successful participation in the FF4EuroHPC Business Experiment and the newest #FFplus Innovation Study. 🎁 𝐖𝐡𝐚𝐭 𝐚𝐝𝐯𝐢𝐜𝐞 𝐰𝐨𝐮𝐥𝐝 𝐡𝐞 𝐠𝐢𝐯𝐞 𝐭𝐨 𝐨𝐭𝐡𝐞𝐫 𝐒𝐌𝐄𝐬 𝐭𝐡𝐚𝐭 𝐡𝐚𝐯𝐞𝐧’𝐭 𝐲𝐞𝐭 𝐞𝐱𝐩𝐥𝐨𝐫𝐞𝐝 𝐭𝐡𝐞 𝐮𝐬𝐞 𝐨𝐟 𝐇𝐏𝐂 𝐚𝐧𝐝 𝐀𝐈 𝐢𝐧 𝐭𝐡𝐞𝐢𝐫 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬? "𝑀𝑦 𝑎𝑑𝑣𝑖𝑐𝑒 𝑡𝑜 𝑜𝑡ℎ𝑒𝑟 𝑆𝑀𝐸𝑠 𝑖𝑠 𝑠𝑖𝑚𝑝𝑙𝑒: 𝑑𝑜𝑛’𝑡 ℎ𝑒𝑠𝑖𝑡𝑎𝑡𝑒 𝑡𝑜 𝑡𝑟𝑦 𝐻𝑃𝐶 𝑎𝑛𝑑 𝐴𝐼 𝑖𝑛 𝑦𝑜𝑢𝑟 𝑑𝑎𝑖𝑙𝑦 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛𝑠—𝑒𝑚𝑏𝑟𝑎𝑐𝑒 𝑡ℎ𝑒𝑚 𝑎𝑠 𝑡𝑜𝑜𝑙𝑠 𝑡ℎ𝑎𝑡 𝑐𝑎𝑛 𝑢𝑛𝑙𝑜𝑐𝑘 𝑖𝑛𝑛𝑜𝑣𝑎𝑡𝑖𝑜𝑛 𝑓𝑎𝑟 𝑏𝑒𝑦𝑜𝑛𝑑 𝑦𝑜𝑢𝑟 𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑙𝑖𝑚𝑖𝑡𝑠." 👉 Find the interview here: https://lnkd.in/dt3-EGsi #interview #SME #Businessinnovation #medicine #pharmaceuticindustry

🚨 Just 1 month to go until BIOEMTECH’s 5th Preclinical Workshop. This year's event brings together experts in 🎯 Targeted Radioligand Therapy and 💊 Drug Discovery, for 4 days of scientific exchange, insights and networking. 🔎 Session # 5️⃣ Business of RLT   Novel strategies to prolong tumor retention, overcoming bottlenecks in RLT development and leveraging dendrimer technologies to enhance radiotheranostic assets, this session highlights the business dimension of radioligand therapy and the path from innovation to market: ✅ Andreas Goutopoulos [Actithera]: New strategies for prolonging tumor retention of radioconjugates - An example from FAP‑directed RLT ✅ Jeff Norenberg [iSeek Biopharma]: Current and practical bottlenecks in RLT development ✅ Jeremy Paull [Starpharma]: Leveraging dendrimer technology to enhance radiotheranostic assets: A translational and commercial perspective Don’t miss the chance to join a unique mix of academic and industry voices shaping the future of targeted radionuclide therapies. 👉 Check the comments for the links! #DrugDiscovery #PreclinicalResearch #TargetedRadioligandTherapy #Radiopharmaceuticals #DendrimerTechnology

🚨 Just 1 month to go until BIOEMTECH’s 5th Preclinical Workshop. This year's event brings together experts in 🎯 Targeted Radioligand Therapy and 💊 Drug Discovery, for 4 days of scientific exchange, insights and networking. 🔎 Session # 4️⃣ Preclinical vectors: targets and probes   From novel targets and innovative probes to imaging strategies and ADC-based approaches, this session explores how preclinical vectors are shaping the development of radioligand therapies: ✅ Gareth Smith [Telix Pharmaceuticals Limited]: Current and emerging targets for radiopharmaceutical therapy ✅ Anne Bredenbeck [3B Pharmaceuticals GmbH]: Advances in probes for RLT ✅ Syed Nuruddin, PhD [Norsk medisinsk syklotronsenter AS]: Imaging as a guide to RLT development ✅ SUJIET PUTHENVEETIL [AstraZeneca]: Guiding RLT development through ADCs 💡 The session will conclude with a panel discussion on “Guided from diagnostics to create therapeutics”, bringing all perspectives together. Don’t miss the chance to join a unique mix of academic and industry voices shaping the future of targeted radionuclide therapies. 👉 Check the comments for the links! #DrugDiscovery #PreclinicalResearch #TargetedRadioligandTherapy #Radiopharmaceuticals #ADCs #RLTProbes

🚨 Just 1 month to go until BIOEMTECH’s 5th Preclinical Workshop. This year's event brings together experts in 🎯 Targeted Radioligand Therapy and 💊 Drug Discovery, for 4 days of scientific exchange, insights and networking. 🔎 Session #2️⃣ Preclinical tools - models, isotopes & dosimetry From animal and non-animal models to alpha isotopes and dosimetry strategies, this session brings together top experts to cover the foundations of preclinical research in radiopharmaceuticals: ✅ Ada Repetto-Llamazares [NucliThera]: Animal models to investigate your drug ✅ Teodor Yordanov [Angios FlexCo]: Non-animal models to investigate your drug ✅ Marion Masitsa M. [ARTBIO]: Exploring the ideal alpha isotope for targeted therapy ✅ Mark Konijnenberg [Erasmus MC]: Dosimetry – current status, challenges and translation aspects 💡 The session will conclude with a panel discussion on “Alpha emitters and ideal isotopes for therapy”, bringing all perspectives together. Don’t miss the chance to join a unique mix of academic and industry voices shaping the future of targeted radionuclide therapies. 👉 Check the comments for the links! #DrugDiscovery #PreclinicalResearch #TargetedRadioligandTherapy #Radiopharmaceuticals #AlphaEmitters #Dosimetry

🏄♀️ Get ready for EuroHPC #UserDays2025! This year’s program brings together outstanding experts, interactive sessions, and two fantastic venues ✨ Here are just some of the speakers and moderators you can look forward to: 🔹 “Accessing EuroHPC Support Services” – Natalie Lewandowski, Guy Lonsdale, Laura Morselli 🔹 “Engineering” – kaare mikkelsen, Arivazhagan Geetha Balasubramanian, Chris Richardson 🔹 “Artificial Intelligence for Science” – Eske Christiansen, Panagiotis Papadimitroulas, Florian Berberich …and many more leading voices in #HPC, #AI, and cutting-edge research! Don’t miss your chance to: ✔ Explore the latest HPC and AI breakthroughs ✔ Connect with researchers, industry, and innovators ✔ Learn how EuroHPC support services accelerate your projects 💡 Check out the full program to discover more topics and speakers and secure your place today! https://lnkd.in/eYnY-xrD DeiC EuroHPC Joint Undertaking (EuroHPC JU) EuroCC 2 and EuroCC4SEE FFplus CASTIEL project